Outlook Therapeutics submits CMS application for permanent J-code for LYTENAVA
OTLK•Outlook Therapeutics filed an application with CMS for a permanent, product-specific J-code for LYTENAVA, targeting a clearer U.S. reimbursement pathway ahead of a planned commercial launch before year-end 2026.
1. Application seeks J-code
Outlook Therapeutics filed an HCPCS Level II application with CMS seeking a permanent, product-specific J-code for LYTENAVA. The move targets a clearer U.S. reimbursement pathway ahead of the planned commercial launch before year-end 2026; CMS review does not assure assignment or guarantee coverage or payment by Medicare or commercial insurers.
